Withanolide A: synthesis and structural requirements for neurite outgrowth†

Cite this: *Chem. Sci.*, 2013, **4**, 2851

Raphael Liffert,^{‡a} Johannes Hoecker,^{‡a} Chandan K. Jana,^{§a} Tom M. Woods,^{¶a} Patrick Burch,^a Henning J. Jessen,^{||a} Markus Neuburger^b and Karl Gademann^{*a}

The exploration of different routes leading to the stereoselective synthesis of the neurotogenic steroid withanolide A is reported in full detail. Notable features of the synthesis include a Corey–Seebach homologation, a vinylogous aldol reaction, a singlet oxygen Schenck-ene reaction, and finally, a late-stage Wharton transposition. Semi-synthetic elaboration of the natural product resulted in 15 derivatives allowing a better understanding of its inherent reactivity pattern as well as its biological properties related to neuronal differentiation and neurite outgrowth.

Received 8th March 2013

Accepted 21st April 2013

DOI: 10.1039/c3sc50653c

www.rsc.org/chemicalscience

Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by amyloid plaque formation, dysfunctional neurons and loss of cognitive functions.^{1a} The number of people suffering from this disease is increasing at an alarming rate, with death occurring approximately 9 years after diagnosis.² The pathogenesis of AD is yet to be fully understood, and both genetic and environmental factors have been suggested to contribute to its progress.³ Currently, dementia is treated mainly with acetylcholine esterase inhibitors that delay the progression rather than actually restore brain function. Due to the prevalence of AD and the nonexistence of long-term therapies, there is a strong requirement to find new drug leads for the therapy of AD and associated diseases.^{1b}

The roots of *Withania somnifera*, also known as ashwagandha (Indian ginseng), are utilized in traditional ayurvedic medicine to improve the cognitive performance of the elderly.⁴ In addition, they have been frequently used in the context of anti-aging, memory reconstruction⁴ and more recently as cognitive enhancers⁵ for healthy subjects. Withanolide A (**1**) isolated from

the roots of *Withania somnifera*,⁶ constitutes one of the most active compounds in the methanolic extracts of ashwagandha and has been demonstrated to possess strong pharmacological properties with regard to axonal outgrowth, regeneration of neurites and recovery of damaged synapses in mice.^{4,7} This pharmacological evidence encouraged us to further investigate this natural product beyond the recently completed first total synthesis of the steroid **1**,⁸ and to prepare derivatives for structure activity relationship (SAR) studies.

Withanolide A is a highly oxygenated steroidal lactone offering several challenges in the context of its synthesis (Fig. 1). The natural product family of the withanolides is characterized by an A, B, C, D steroid ring system and a lactone side chain (SC).^{9,10} Withanolide A possesses a reactive enone moiety in the A ring, an epoxy alcohol in the B ring, as well as a tetrasubstituted unsaturated lactone as a side chain. The main synthetic challenges arise from the stereoselective construction of the side chain and the oxidation pattern of the A and B ring and the diastereoselective instalment of a tertiary alcohol at C-20. Departing from a cheap and commercially available starting material, we chose pregnenolone **2** for our synthetic endeavours.

In this edge article, we report in full detail on different synthetic approaches to the target withanolide A culminating in the first synthesis of this steroid. In addition, semi-synthesis

^aDepartment of Chemistry, University of Basel, St. Johannis-Ring 19, 4056 Basel, Switzerland. E-mail: karl.gademmann@unibas.ch; Fax: +41 612-671-105

^bLaboratory for Chemical Crystallography, University of Basel, Spitalstrasse 51, 4056 Basel, Switzerland

† Electronic supplementary information (ESI) available: Experimental procedures, analytical data, crystal data and CIF file for alcohol **22**. CCDC 924130. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c3sc50653c

‡ Both authors contributed equally to this work.

§ Present address: Department of Chemistry, Indian Institute of Technology Guwahati, 781039 Guwahati, Assam, India.

¶ Present address: Department of Chemistry, The University of Auckland, 23 Symonds Street, Auckland CBD, New Zealand.

|| Present address: Institute of Organic Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.

Fig. 1 Structures of withanolide A (**1**) and pregnenolone (**2**).

studies not only allowed the reactivity of the different parts of the steroidal structure to be assessed, but also enabled the generation of 15 derivatives resulting in detailed SAR studies on neuronal differentiation and neurite outgrowth in human neuroblastoma cells.

Results and discussion

Evaluation of different routes to withanolide A

We initially identified the presence of the α,β -unsaturated lactone in the side chain as the most labile fragment of withanolide A (**1**), which led us to embark on a strategy involving late instalment of this pyranone. It was further anticipated that we could use a procedure developed by Ikekawa and co-workers¹¹ to form the lactone side chain motif from a simple steroidal aldehyde precursor by a vinylogous Mukaiyama aldol reaction in the last step, after the B and A rings had been completed.

The approach started with the known homologation required for the side chain by a Corey-Seebach umpolung reaction.¹² Therefore, the 3β -OH group of commercially available pregnenolone (**2**) was protected as its TBS ether and treatment of the resulting ketone with lithiated dithiane afforded the tertiary alcohol **3** (Scheme 1) in 95% yield (dr 15 : 1). Several methods were investigated to cleave the dithiane moiety in **3**, with the main concern being the stability of the TBS protecting group. Methods such as HgCl_2 , NBS and I_2 both with and without addition of base were largely unsuccessful and resulted in either the loss of the TBS group as well as the dithioacetal or more complex mixtures. However, treatment of dithiane **3** with NCS in a CH_2Cl_2 - H_2O mixture in an open vessel at room temperature afforded the desired α -hydroxy aldehyde in

a good yield. Protection of the C-20 tertiary alcohol as its MOM ether **4** was achieved by treating a solution of the alcohol and *N,N*-diisopropylethylamine (DIPEA) with MOMI and refluxing the reaction overnight (in 69% over 2 steps). The efficiency of the reaction was found to be dependent on the quality of the starting materials, in particular, NaI was dried under high vacuum at 100 °C for several hours and MOMCl was freshly distilled before use. A simple filtration through a short pad of silica was sufficient to provide material for the next step. Reduction of aldehyde **4** with NaBH_4 in MeOH proceeded uneventfully and furnished the desired alcohol as a white solid, which was used directly in the next step. Treatment of the alcohol with NaH followed by addition of PMBCl and a catalytic amount of tetrabutylammonium iodide (TBAI) afforded the desired differentially protected triol **5**.

With the homologated triol **5** in hand the stage was set to target the functionalization on the B ring. Epoxidation of the double bond proceeded smoothly affording a 4.1 : 1 diastereomeric ratio of the desired α -epoxide **5** in 71% yield over three steps. Performing the reaction at 0 °C slightly improved the selectivity, but lower temperatures (e.g. -15 °C) reduced the rate of reaction. Following a method of Sharpless and Lauer for the oxidative opening of epoxides,¹³ reduction of $(\text{PhSe})_2$ with NaBH_4 in EtOH followed by addition to the MOM protected epoxide and further treatment with H_2O_2 , afforded the desired allylic alcohol **6** in 48% yield accompanied by recovered starting material. The undesired β -epoxide was not reactive towards these conditions and separation was easily achieved. Allylic alcohol **6** was sensitive to acidic conditions and was prone to rearrange to the thermodynamically more stable trisubstituted olefin. The allylic alcohol **6** was then further transformed to the epoxy alcohol by simple treatment

Scheme 1 Approach towards the synthesis of MOM-protected withanolide A derivative **11**.

with *m*CPBA in CH_2Cl_2 . This directed epoxidation (by the tertiary OH group) was found to be completely selective and high yielding and completed the functionalization of the B-ring. Deprotection of the TBS group by treatment with tetrabutylammonium fluoride (TBAF) furnished compound **7** bearing a free OH group at C3.

For the subsequent transformation of the A ring to the desired enone, allylic oxidation reactions turned out to be unsuccessful,¹⁴ and therefore Saegusa oxidation was chosen instead.¹⁵ After oxidation of the secondary OH group by TPAP, the formed TIPS enol ether was treated with 1 equivalent of $\text{Pd}(\text{OAc})_2$ in CH_3CN and the desired α,β -unsaturated ketone **8** was isolated in 43% yield (over three steps). Attempts to reduce the amount of $\text{Pd}(\text{OAc})_2$ employed by adding benzoquinone as a co-oxidant led to poor yields of the desired product. Epoxidation of the unsaturated ketone under basic conditions gave the bis-epoxide in 54% yield with complete diastereoselectivity. K_2CO_3 was found to be the best choice of base; stronger bases such as NaOH and KO^tBu gave complex mixtures of products. With the keto epoxide in hand the stage was set for the Wharton transposition. Wharton's original conditions ($\text{N}_2\text{H}_4 \cdot \text{H}_2\text{O}$, AcOH) afforded poor yield of the desired allylic alcohol.¹⁶ However, in 1989 Dupuy and Luche reported modified conditions for the Wharton transposition using basic conditions,¹⁷ and in such a way, the conversion to the allylic alcohol was improved. Subsequent deprotection of the PMB protecting group using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) proceeded smoothly and afforded triol **9** in a 50% yield over the two steps. The primary and secondary diols were then oxidized simultaneously with TPAP, NMO to complete the A ring functionalities and to furnish the desired C-22 aldehyde **10**. In order to complete the synthesis of withanolide A (**1**), the side chain lactonization was evaluated next. However, despite using a variety of conditions, the final lactonization to **11** could not be performed successfully. It is likely that the presence of the enone in the A ring is detrimental to this approach, which therefore had to be abandoned.

Preparation of withanolide A

Having realized the sensitivity of the A ring, both from the unsuccessful synthetic attempt as discussed above, and from the ease of its functionalization in the context of semi-synthesis studies (*vide infra*), we sought to introduce this enone last in the synthetic sequence. In addition, these studies hinted at the stability of the side chain lactone, which led us to choose its early instalment (Scheme 2). Therefore, following the procedure developed by Ikekawa and co-workers,^{10a,11} the aldehyde **4** was reacted with the vinylogous enolate from ethyl 2,3-dimethylbut-2-enoate and LiHMDS in a mixture of THF and DMPU *via* a stereoselective aldol reaction to deliver the unsaturated lactone side chain **12** in very good yield and stereoselectivity (87%, dr 93 : 7). Again, protection of the tertiary alcohol as the MOM ether was found to be key for this transformation. Unselective side-reactions during exposure to strong bases during its introduction were avoided, and the relatively small size of the

Scheme 2 Synthesis of withanolide A (**1**) from aldehyde **4**.

MOM group meant that the unhindered nucleophilic attack of the formed enolate on the aldehyde was possible.

We next proceeded to install the correct oxidation pattern in the B ring of withanolide A. The challenge as previously described consisted in the regioselective instalment of the epoxy alcohol in the presence of the unsaturated lactone. Having struggled with limitations associated with phenyl-selenium-chemistry as detailed above, we recognized the singlet oxygen mediated photo-oxygenative olefin migration (Schenck-ene reaction¹⁸) as a straightforward method¹⁹ for the preparation of the allylic alcohol **13** from an unfunctionalized olefin. Therefore, olefin **12** was allowed to react with singlet oxygen generated *in situ* from O_2 in the presence of *meso*-tetraphenylporphyrin (TPP) as sensitizer under irradiation with Na-light. The formed hydroperoxide was *in situ* reduced by PPh_3 to the allylic alcohol **13** in good yield (61%). Directed epoxidation of allylic alcohol **13** mediated by *m*CPBA proceeded as anticipated to provide, after removal of all protecting groups by exposure to HCl, the desired epoxy alcohol **14** in excellent yield.

It should be pointed out that we have, by design, chosen to avoid any protecting groups for the remaining elaboration of triol **14** therefore exploiting the inherent reactivity of this steroid derivative. The final installation of the correct oxidation pattern in the A ring started by oxidation of the triol **14** first by TPAP and NMO and second by exposure to 2-iodoxybenzoic acid (IBX)²⁰ to provide the corresponding enone **15** (77%). The unsaturated ketone **15** was then converted with basic aqueous H_2O_2 (Triton B)²¹ to the epoxy ketone. The stage was again set

for the Wharton transposition on the epoxy ketone substrate. Therefore, the intermediate was subjected to reaction with hydrazine ($\text{N}_2\text{H}_4 \cdot \text{HCl}$) in the presence of base to furnish the rearranged allylic alcohol.¹⁷ This reaction proceeded smoothly to give, after subsequent oxidation by pyridinium dichromate (PDC), withanolide A (**1**) in good yield (30% over three steps).

All analytical data (^1H and ^{13}C NMR, optical rotation, UV, m.p.) for the synthetic and isolated natural product were found to be in full agreement. The final proof of identity of the synthetic and isolated natural sample of **1** was established by co-injection and analysis of natural and synthetic samples by HPLC.

Semi-synthesis of new derivatives of withanolide A

In order to access additional derivatives for biological studies, we initiated semi-synthesis studies on withanolide A (**1**). This steroidal lactone was therefore isolated from the dried and powdered roots of *Withania somnifera* (ashwagandha) by a modification of a known procedure.⁶ After an extensive survey of different approaches commonly employed in semi-synthesis to functionalize withanolide A (**1**), we found that only the A ring was susceptible to chemical modification. In addition, A ring derivatives bearing *e.g.* a β -hydroxy group like sominone—an aglycon of withanoside IV—were found to display neuritogenic properties as shown from the work of Tohda and co-workers,²² lending further support to the hypothesis that compounds with variations in this ring may retain biological activity.

We first targeted the regioselective 1,2-reduction of withanolide A resulting in the allylic alcohol **16**, which was envisioned to serve as a building block for a variety of new functionalities at C-1. The reduction was performed under Luche conditions,²³ using CeCl_3 and NaBH_4 in a mixture of MeOH and CHCl_3 in 75% yield with complete diastereoselectivity (Scheme 3). Surprisingly, the same stereochemical outcome was observed when using simple NaBH_4 without additional CeCl_3 to coordinate the ketone function, as established by an X-ray crystal structure analysis in an earlier study.⁸ Unfortunately, all attempts to further functionalize the C-1

hydroxy group or acetylation reactions were unsuccessful. Regioselective hydrogenation of the 2,3-double bond was performed by using 2 mol% Crabtree's catalyst under a hydrogen atmosphere of 10 bar to obtain the saturated alcohol **17**.

Due to the problems associated with the manipulation of the allylic alcohol **16**, a new strategy for the derivatization of the natural product needed to be developed. Tohda *et al.* showed in their studies on sominone that steroids bearing a C3-OH group can serve as useful intermediates.²² Therefore we targeted a synthetic route from withanolide A to C3-OH derivatives, as shown in Scheme 4. The synthetic plan relied on epoxidation of withanolide A (**1**) followed by epoxide opening under reductive conditions, which was used in the context of B ring functionalization (see **5** to **6**, Scheme 1). It should be pointed out that again no protecting groups were introduced and that these reagents have been found to be compatible with the functional group manifold present in the A and B rings and the side chain lactone.

We first evaluated the epoxidation of withanolide A (**1**) by using the conditions developed in the course of the total synthesis. Exposure of steroid lactone **1** to aqueous H_2O_2 in the presence of Triton B afforded epoxide **18** in 48% yield on small scale. Unfortunately, the reaction was dependent on the scale, and the use of 100 mg of **1** resulted in a dramatic loss of material (11% yield). After extensive investigation of different conditions (solvent, base and oxidizing reagents)²⁴ we found the fluoride-promoted epoxidation of α,β -unsaturated carbonyl compounds described by Yoshikoshi and co-workers was compatible with our system.²⁵ By using their protocol, the use of TBAF as base and H_2O_2 or *tert*-butyl hydroperoxide (*t*BuOOH) as oxidation reagent was found to be superior. These conditions improved the yield reliably to 84% (on a 150 mg scale), with CH_2Cl_2 as solvent and *t*BuOOH as oxidant.

The organoselenium-mediated reduction of α,β -epoxy ketone **18** to the corresponding β -hydroxy ketone was investigated next. Alcohol **19** was obtained in good yields on adding an ethanolic solution of the active reagent ($[\text{Na}[\text{PhSeB}(\text{OEt})_3]]$) and AcOH to a solution of epoxy ketone **18** in CH_2Cl_2 .²⁶ The chemical shift of the equatorial C3-H in **19** was found to be at 4.11 ppm, whereas the axial proton reported for the C3 diastereomeric natural product²⁷ resonates at 4.91 ppm. This large difference might be caused by the influence of the neighbouring hydroxyl group on the axial proton and could be observed later for the allylic alcohols **22** and **24** as well. Efficient acetylation of alcohol **19** under standard conditions (Ac_2O , DMAP, Et_3N in CH_2Cl_2) delivered acetate **20** in 77% yield without any detectable amount of eliminated side-product. This example demonstrates the feasibility of introducing carboxylate esters of choice at this position. Reduction of ketone **19** was performed using NaBH_4 and afforded a new baseline spot by TLC. UPLC-MS confirmed formation of tetraol **21**, but the isolation of this hydrophilic compound turned out to be difficult.²⁸ Finally, work-up with a saturated solution of Rochelle salt liberated tetraol **21** and allowed the characterization of its structure by NMR spectroscopy. The stereochemical outcome of **21** was anticipated from the NaBH_4 mediated reduction of withanolide A (**1**) and could be confirmed by NOESY NMR spectroscopy. The structural

Scheme 3 Regioselective reduction of withanolide A.

Scheme 4 Semi-synthetic transformations of withanolide A to access A ring derivatives without the enone moiety.

assignment was supported by NOE cross peaks of H-1 with H-19 and H-2 and H-4, respectively.

Concerning the targeted introduction of substituents at C3, another possibility could be the transformation of epoxy ketone **18** to allylic alcohol **22** (Scheme 4). For this manipulation, the Wharton carbonyl transposition was investigated using conditions as discussed earlier. Consequently, epoxy ketone **18** was treated with $\text{NH}_2\text{NH}_2 \cdot \text{HCl}$ in the presence of Et_3N in CH_3CN ,¹⁶ but no product formation was observed. Typical acidic conditions with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ and AcOH for Wharton transposition are reported in various publications and O'Doherty and Wang described a method using more equivalents of both reagents $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ and AcOH to improve the yield.²⁹ They also noted that a protic solvent can be favourable for certain substrates. Due to the low solubility of **18** in methanol, the reaction was successfully conducted in a 1 : 1 mixture of methanol and CH_2Cl_2 to obtain the allylic alcohol **22** in 61% yield after 3 h at room temperature. The structure of alcohol **22** was confirmed by X-ray analysis of the crystal structure and the configuration of the $3\alpha\text{-OH}$ group was retained from the epoxidation step.

Next, we investigated the introduction of functional groups at the newly formed secondary alcohol in order to probe if alcohol **22** can be attached to various residues such as, for example, sugars known from the studies on sominone by Tohda and co-workers. Acetylation of allylic alcohol **22** was performed again under standard acetylation conditions and afforded acetate **23** in good yield. This indicates that alcohol **22** is also a feasible precursor for further manipulations. Inversion of the C3 hydroxyl group in **22** was accomplished using the Mitsunobu procedure. Esterification with *para*-nitrobenzoic acid, followed by saponification with aqueous NaOH in the presence of tetrabutylammonium hydroxide (TBAH) as phase-transfer catalyst afforded 3β -allylic alcohol **24** in 50% yield.

Additionally, the double bond of allylic alcohol **22** was reduced with 10 mol% Pd on activated charcoal. Quantitative conversion provided alcohol **25** as an inseparable 1 : 1 mixture with the isomerized saturated ketone **14a** (Scheme 5), an

intermediate obtained in our synthesis of **1** (see Scheme 2).³⁰ Given that we were interested in alcohol **25**, Crabtree's catalyst turned out to be efficient for the hydrogenation of **22** to yield alcohol **25** quantitatively without the isomerized product.

Oximes of withanolide A as prodrugs may improve the solubility as well as the bioavailability *in vivo*. Additionally, oximes were found to be the only possibility to modify the C1 position of natural product **1** (Scheme 6). The oximes **26–30** were easily obtained by heating withanolide A **1** or the derived epoxide **18** and the corresponding hydroxylamine hydrochloride in pyridine at 70 °C for 1 to 2 days in good yields.

Biological evaluation

The natural product **1** and several semi-synthetic derivatives were tested in order to determine their neurotogenic properties according to the previously published methods.^{7a,8} Human SH-SY5Y neuroblastoma cells (4×10^4 cells per cm^2) were grown on collagen I coated 24-well plates in minimal essential medium (MEM) with 5% fetal bovine serum (FBS). After incubation for 4 days in the presence of the corresponding compounds (1 μM ,

Scheme 5 Hydrogenation of allylic alcohol **22**.

Scheme 6 Oxime formation of withanolide A.

0.1% DMSO), the cells were examined under a phase contrast microscope after fixation (5% formaldehyde in PBS buffer solution), stained (modified Giemsa stain), and the differentiated cells were counted. For each compound nine pictures from random areas of three different wells were taken (for representative micrographs see ESI†). At least 500 cells were counted for each individual compound. The criterion for a differentiated cell was at least one neurite with a length of more than 50 μm . In control experiments DMSO (0.1%) was used as a negative control. The results are summarized in Fig. 2.

While it is difficult to draw quantitative conclusions from the biological assays, several facts became apparent: compounds **16**, **22**, **24**, and **26** showed similar activities when compared to withanolide A with regard to neurite outgrowth stimulating activity in SH-SY5Y cells. The compounds **18**, **23**, and **27–30** showed in fact less activity than withanolide A, to the extent that some compounds can be hardly distinguished from the solvent control in these phenotypic assays. It appears that there is a correlation between the size of the attached group and activity. For example, the hydroxylamine **26** shows increased activity than the corresponding and sterically more demanding oximes **27–30**. The same trend was observed for allyl alcohol **22** and its acetate **23**. Additionally, the chemically reactive enone moiety of withanolide A in the A ring might not be required for neuroactive properties, as the allylic alcohols **16** and **22** retained activity.

Fig. 2 Neurite outgrowth activity of DMSO blank, withanolide A and derivatives in human SH-SY5Y cells with MEM as cell-medium. Error bars denote SEM.

Conclusions

In conclusion, we have developed the first successful synthesis of the pharmacologically important steroid withanolide A by adjusting the route based on the understanding of the inherent reactivity of the natural product by semi-synthesis studies. Notable features of this synthesis include (1) a highly diastereoselective Schenck-ene reaction, (2) a minimal protecting group strategy exploiting the inherent reactivity pattern in the endgame and (3) a Wharton transposition for the A ring formation. Further, we have synthesised more than 15 derivatives of withanolide A directly from the isolated natural product. Therefore, we developed two new synthetic routes that allow the generation of a hydroxyl group at C3 and thereby open the door for attachment of a variety of functionalities. Both key intermediates, the β -hydroxy ketone **19** and the allylic alcohol **22**, were synthesised in high yields and full diastereoselectivity using simple reaction conditions in two steps from **1**.

In addition, biological studies of neurite outgrowth in human SH-SY5Y cells demonstrated the dependence of neurotogenic properties on the size rather than the functionality in the A ring of the evaluated compounds. Three compounds indicated a comparable or higher neurite outgrowth activity in cell assays than withanolide A itself. Further investigations towards the modification of functional groups at C-3 of withanolide A would probably give access to more sophisticated candidates and allow for the manipulation of properties such as solubility or bioavailability.

Acknowledgements

Financial support by the Swiss National Science Foundation (200021-144028 and PE002-117136/1) and DFG (Project JE 572/1-1) is gratefully acknowledged. We thank Novartis for supporting part of this work (Novartis Early Career Award 2010 to K.G.). We thank Dr. Hideki Miyatake Odozabal for proof-reading of this manuscript.

Notes and references

- (a) Alzheimer's Disease International, World Alzheimer Report, 2012, pp. 1–13; (b) for selected recent studies on neurotogenic compounds, see, for example: S. P. Waters, Y. Tian, Y.-M. Li and S. J. Danishefsky, *J. Am. Chem. Soc.*, 2005, **127**, 13514–13515; R. M. Wilson and S. J. Danishefsky, *Acc. Chem. Res.*, 2006, **39**, 539–549; M. Rawat, C. I. Gama, J. B. Matson and L. Hsieh-Wilson, *J. Am. Chem. Soc.*, 2008, **130**, 2959–2961; A. Bisai, S. P. West and R. Sarpong, *J. Am. Chem. Soc.*, 2008, **130**, 7222–7223; H. J. Jessen, D. Barbaras, M. Hamburger and K. Gademann, *Org. Lett.*, 2009, **11**, 3446–3449; A. P.-J. Chen, C. C. Müller, H. M. Cooper and C. M. Williams, *Org. Lett.*, 2009, **11**, 3758–3761; Z. Wang, S.-J. Min and S. J. Danishefsky, *J. Am. Chem. Soc.*, 2009, **131**, 10848–10849; F. Schmidt, P. Champy, B. Seon-Meniél, X. Franck, R. Raisman-Vozari and B. Figadere, *PLoS One*, 2009, **4**, e6215; S.-W. Jang, X. Liu, C. B. Chan, S. A. France,

- I. Sayeed, W.-X. Tang, X. Lin, G. Xiao, R. Andero, Q. Chang, K. J. Ressler and K.-Q. Ye, *PLoS One*, 2010, **5**, e11528; J. Xu, L. Trzoss, W. K. Chang and E. A. Theodorakis, *Angew. Chem., Int. Ed.*, 2011, **50**, 3672–3676; T. Nishimura, A. K. Unni, S. Yokoshima and T. Fukuyama, *J. Am. Chem. Soc.*, 2011, **133**, 418–419; L. E. Scott, M. Telpoukhovskaia, C. Rodriguez-Rodriguez, M. Merkel, M. L. Bowen, B. D. G. Page, D. E. Green, T. Storr, F. Thomas, D. D. Allen, P. R. Lockman, B. O. Patrick, M. J. Adam and C. Orvig, *Chem. Sci.*, 2011, **2**, 642–648; M. K. M. Tun, D.-J. Wüstmann and S. B. Herzon, *Chem. Sci.*, 2011, **2**, 2251–2253; X. Cheng, N. Harzdorf, Z. Khaing, D. Kang, A. M. Camelio, T. Shaw, C. E. Schmidt and D. Siegel, *Org. Biomol. Chem.*, 2012, **10**, 383–393; E. Elamparuthi, C. Fellay, M. Neuburger and K. Gademann, *Angew. Chem., Int. Ed.*, 2012, **51**, 4071–4073; J. Hoecker, R. Liffert, P. Burch, R. Wehlauch and K. Gademann, *Org. Biomol. Chem.*, 2013, DOI: 10.1039/c3ob40106e; L. Trzoss, J. Xu, M. H. Lacoske, W. C. Mobley and E. A. Theodorakis, *Chem.–Eur. J.*, 2013, DOI: 10.1002/chem.201300198.
- 2 For a review, see: P. Williams, A. Sorribas and M.-J. R. Howes, *Nat. Prod. Rep.*, 2011, **28**, 48–77.
 - 3 D. K. Lahiri, B. Maloney, M. R. Basha, Y. W. Ge and N. H. Zawia, *Curr. Alzheimer Res.*, 2007, **4**, 219–228.
 - 4 For a review on the neuroactive properties of ashwagandha, see: S. Jain, S. D. Shukla, K. Sharma and M. Bathnagar, *Phytother. Res.*, 2001, **15**, 544–548.
 - 5 <http://www.cerebralhealth.com/brainhealthsupplements.php>.
 - 6 S. S. Subramanian, P. D. Sethi, E. Glotter, I. Kirson and D. Lavie, *Phytochemistry*, 1971, **10**, 685–688.
 - 7 For neuroactive properties of withanolide A, see: (a) T. Kuboyama, C. Tohda, J. Zhao, N. Nakamura, M. Hattori and K. Komatsu, *NeuroReport*, 2002, **13**, 1715–1720; (b) J. Zhao, N. Nakamura, M. Hattori, T. Kuboyama, C. Tohda and K. Komatsu, *Chem. Pharm. Bull.*, 2002, **50**, 760–765; (c) T. Kuboyama, C. Tohda and K. Komatsu, *Br. J. Pharmacol.*, 2005, **144**, 961–971.
 - 8 C. K. Jana, J. Hoecker, T. Woods, H. J. Jessen, M. Neuburger and K. Gademann, *Angew. Chem., Int. Ed.*, 2011, **50**, 8407–8411.
 - 9 For reviews on withanolide structures, bioactivities and synthetic approaches, see: (a) L.-X. Chen, H. He and F. Qiu, *Nat. Prod. Rep.*, 2011, **28**, 705–740; (b) I. Kirson and E. Glotter, *J. Nat. Prod.*, 1981, **44**, 633–647; (c) N. V. Kovganko and Z. N. Kahkan, *Chem. Nat. Compd.*, 1997, **33**, 133–145.
 - 10 For synthetic investigations on withanolides, see: (a) K. Gamoh, M. Hirayama and N. Ikekawa, *J. Chem. Soc., Perkin Trans. 1*, 1984, 449–454; (b) A. Perez-Medrano and P. A. Grieco, *J. Am. Chem. Soc.*, 1991, **113**, 1057–1059; (c) E. Glotter, S. Kumar, M. Sahai, A. Goldman, I. Kirson and M. Medelovici, *J. Chem. Soc., Perkin Trans. 1*, 1991, 739–745; (d) M. Ishiguro, A. Kajikawa, T. Haruyama, Y. Ogura, M. Okubayashi, M. Morisaki and N. Ikekawa, *J. Chem. Soc., Perkin Trans. 1*, 1975, 2295–2302; (e) P. Neogi, M. Kawai, Y. Butsugan, Y. Mori and M. Suzuki, *Bull. Chem. Soc. Jpn.*, 1988, **61**, 4479–4481.
 - 11 M. Ishiguro, M. Hirayama, H. Saito, A. Kajikawa and N. Ikekawa, *Heterocycles*, 1981, **15**, 823–834.
 - 12 B. B. Shingate, B. G. Hazra, V. S. Pore, R. G. Gonnade and M. Bhadbhade, *Tetrahedron*, 2007, **63**, 5622–5635.
 - 13 K. B. Sharpless and R. F. Lauer, *J. Am. Chem. Soc.*, 1973, **95**, 2697–2699.
 - 14 (a) J.-Q. Yu, H.-C. Wu and E. J. Corey, *Org. Lett.*, 2005, **7**, 1415–1417; (b) A. J. Catino, R. E. Forslund and M. P. Doyle, *J. Am. Chem. Soc.*, 2004, **126**, 13622–13623.
 - 15 Y. Ito, T. Hirao and T. Saegusa, *J. Org. Chem.*, 1978, **43**, 1011–1013.
 - 16 P. S. Wharton and D. H. Bohlen, *J. Org. Chem.*, 1961, **26**, 3615–3616.
 - 17 C. Dupuy and J. L. Luche, *Tetrahedron*, 1989, **45**, 3437–3444.
 - 18 (a) G. O. Schenck, DE-B 933925, 1943; (b) G. O. Schenck, *Naturwissenschaften*, 1948, **35**, 28–29.
 - 19 (a) W. Adam and E. Staab, *Liebigs Ann. Chem.*, 1988, 757–759; (b) for a review, see: M. Prein and W. Adam, *Angew. Chem., Int. Ed. Engl.*, 1996, **35**, 477–494.
 - 20 K. C. Nicolaou, T. Montagnon and P. S. Baran, *Angew. Chem., Int. Ed.*, 2002, **41**, 993–996.
 - 21 M. T. Barros, C. D. Maycock and M. R. Ventura, *Tetrahedron*, 1999, **55**, 3233–3244.
 - 22 (a) T. Kuboyama, C. Tohda and K. Komatsu, *Eur. J. Neurosci.*, 2006, **23**, 1417–1426; (b) C. Tohda and E. Joyashiki, *Br. J. Pharmacol.*, 2009, **157**, 1427–1440.
 - 23 A. L. Gemal and J. L. Luche, *J. Am. Chem. Soc.*, 1981, **103**, 5454–5459.
 - 24 (a) F. E. Ziegler, K.-J. Hwang, J. F. Kadow, S. I. Klein, U. K. Pati and T.-F. Wang, *J. Org. Chem.*, 1986, **51**, 4573–4579; (b) F. J. Moreno-Dorado, F. M. Guerra, F. J. Aladro, J. M. Bustamante, Z. D. Jorge and G. M. Massanet, *Tetrahedron*, 1999, **55**, 6997–7010; (c) R. Takagi, K. Tojo, M. Iwata and K. Ohkata, *Org. Biomol. Chem.*, 2005, **3**, 2031–2036.
 - 25 M. Miyashita, T. Suzuki and A. Yoshikoshi, *Chem. Lett.*, 1987, 285–288.
 - 26 (a) M. Miyashita, T. Suzuki and A. Yoshikoshi, *Tetrahedron Lett.*, 1987, **28**, 4293–4296; (b) M. Miyashita, M. Hoshino and A. Yoshikoshi, *Tetrahedron Lett.*, 1988, **29**, 347–350.
 - 27 M. I. Choudhary, S. Yousuf, S. A. Nawaz, S. Ahmed and A. Rahman, *Chem. Pharm. Bull.*, 2007, **52**, 1358–1361.
 - 28 Baran and co-workers reported that similar 1,3,5-trihydroxy cyclohexane steroids showed a tenacity for glass: H. Renata, Q. Zhou and P. Baran, *Science*, 2013, **339**, 59–63.
 - 29 H. Y. Wang and G. A. O'Doherty, *Chem. Commun.*, 2011, **47**, 10251–10253.
 - 30 R. Uma, C. Crévisy and R. Grée, *Chem. Rev.*, 2003, **103**, 27–52.